![Cytochrome P450 CYP1B1(190-198)[Homo sapiens]图片](http://www.cnreagent.com/data/daily/2022/11/01/083051_415137_umcs_1046517.png)
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 1057.24 |
| Formula | C50H80N12O13 |
| Synonyms | H2N-Phe-Leu-Asp-Pro-Arg-Pro-Leu-Thr-Val-OH |
| Solubility | ≥105.7 mg/mL in DMSO; ≥16.53 mg/mL in H2O; ≥35 mg/mL in EtOH |
| Canonical SMILES | NC(C(NC(CC(C)C)C(NC(CC(O)=O)C(N1C(C(NC(CCCNC(N)=N)C(N2CCCC2C(NC(CC(C)C)C(NC(C(C)O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)CC3=CC=CC=C3 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
氨基酸序列NH2-FLDPRPLTV-OH。
细胞色素P450 CYP1B1是二恶英诱导的细胞色素P450家族的外源性代谢酶1。
在HLA-A2Kb转基因小鼠中，使用ZYC300进行免疫，诱导了HLA-A2限制的，CYP1B1190-198（CYP190）多肽特异性的T细胞应答，ZYC300是一种PLG微粒制剂，包含可以编码肿瘤相关抗原CYP1B1的质粒2, 3。
在最后一次免疫完成两周后可以观察到，EPT和ZYC300连续共给引起T细胞应答的逐步上升，EPT与30 μg无效剂量的ZYC300单次给药也能诱导可检测的CD8 + CYP190特异性的T细胞应答。
Figure1. Cytochrome P450 CYP1B1
Figure2. Formula of Cytochrome c fragment (93-108)
C50H80N12O13
Figure3.Location of Cytochrome P450 CYP1B1
The CYP1B1 gene is located on the short (p) arm of chromosome 2 at position 22.2.
参考文献：
1. Murray,G.I., Taylor, M. C.,et al1997; Tumor-specific Expression of Cytochrome P450 CYP1B11.Cancer Research. 57:3026-3031.
2. Luby TM, Cole GA, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor associated antigen cytochrome P450 1B1.Clinical Immunology2004;112(1):45–53.
3. Maecker DH, Sherr RH, Vonderheide MS, von Bergwelt-Baildon MS, Hirano N, Anderson K, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells.Blood2003;102(9):3287–94.
4. Barbon, C. M., Baker, Let al2010 In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization.Vaccine; 28:7852-7864
m.cnreagent.com